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1 
Abstract 
Calciphylaxis, or calcific uremic arteriolopathy, is a vascular ossification-calcification disease involving 
cutaneous or visceral arterioles, with ischemic damage of the surrounding tissues, usually in the setting of 
chronic kidney disease. Pathogenesis is still unclear and probably comprises the participation of vascular 
smooth muscle cells, endothelial cells and macrophages surrounded by a uremic and/or pro-calcifying 
environment. According to the original concept of calcific uremic arteriolopathy coined by Hans Selye, 
risk factors may be divided into sensitizers and challengers and their knowledge is useful in clinical prac-
tice to pre-emptively identify both uremic and non-uremic ‘at risk’ patients and guide treatment. Systemic 
calcific uremic arteriolopathy is a rarity. Cutaneous calcific uremic arteriolopathy is more frequent and 
clinically presents as a first phase of cutaneous hardening and erythema, followed by a second phase of 
ulcerations and scars; these two phases are probably associated with the initial development of arteriolar 
lesion and tissue ischemic damage, respectively. Clinical history, physical examination, laboratory, his-
tology and imaging are the main tools to exclude important differential diagnoses and obtain a definitive 
diagnosis. Treatment is generally unrewarding and consists of rigorous control of comorbid conditions, 
anti-oxidant, anti-inflammatory and antithrombotic strategies, avoidance of iatrogeny and wound and pain 
management. Prognosis remains poor in terms of morbidity and mortality. Efforts should be made to-
wards a greater awareness of calcific uremic arteriolopathy, development of better therapies and im-
provement of clinical outcomes. 
 
Keywords calcific uremic arteriolopathy · calciphylaxis · chronic kidney disease – mineral and 
bone disorders · vascular ossification-calcification · soft tissue calcification 
 
 
Introduction 
 
Chronic kidney disease (CKD) comprises a variety of homeostatic imbalances arising from a severely 
compromised renal function, as well as the influence of cardiometabolic comorbidities. Uremic syndrome 
is an umbrella term for the clinical consequences of these phenomena throughout the body. In particular, 
dysregulation of calcium (Ca) and phosphate (P) metabolism plays a central role in the development of 
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changes in bone (renal osteodystrophy) and extraosseous calcification involving vessels, extraosseous soft 
tissues and other structures [1]. 
Calcification of the vascular tree, also known as vascular ossification-calcification, is a highly preva-
lent complication of CKD. It is a result of multifactorial, coordinated and active osteochondrogenic pro-
cesses occurring in the vessels. Chronic injurious stimuli in certain chronic diseases, namely CKD, pro-
duce an environment of metabolic toxicity in the vasculature favourable to mineralization [2, 3]. 
Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a systemic pathology of extraosseous calci-
fication. Usually, but not always [4], it occurs in the context of CKD and affects dermal, subcutaneous 
and/or visceral arterioles and soft tissues, according to histopathologic and functional studies [5, 6]. Some 
authors view CUA as a pure small-artery disease which should be clearly differentiated from soft tissue 
calcification [7], but CUA is also regarded as one of the five subtypes of calcinosis cutis [8]. 
As a middle ground between these concepts, CUA may be perceived as a vascular ossification-
calcification disease with other associated phenomena in the arterioles and surrounding tissues, leading to 
significant ischemic damage and other dermatologic, soft tissue and/or visceral manifestations [6]. 
This review aims to describe the pathway from the pathophysiologic roots of the disease to the strate-
gies used in the diagnosis and treatment of the CUA patient. 
 
 
Methods 
 
Searches were performed in the electronic PubMed database with combinations of the following 
words: “calciphylaxis”, “calcific uremic arteriolopathy”, “renal osteodystrophy”, “vascular calcification”, 
“visceral calciphylaxis” and “systemic calciphylaxis”. Related articles mentioned in the reference sections 
of some of the retrieved articles were also considered. Articles not written in English or without accessi-
ble full texts were excluded. 
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A multi-layered pathogenesis 
 
Active vascular ossification-calcification processes in the tunica media of the arterioles are the anchor 
of the development of CUA [9-11]. However, they are not enough to explain the whole clinical picture, 
correctly establish the diagnosis or justify some of the therapeutic strategies currently used [12]. 
Neither a step-by-step pathogenic pathway nor the relative weight of all the factors involved are 
known. It is thought that CUA is a multifactorial disease ensuing from an intricate interaction of events 
happening in all the arteriolar layers, arteriolar lumen and surrounding skin, soft tissues, and/or visceral 
parenchyma. This leads to medial calcification without associated intimal calcification or vasculitic 
changes and one or more of the following alterations: extracellular matrix (ECM) remodelling, subintimal 
fibrosis, thrombus formation and tissue inflammation, calcification, ischemia and necrosis [3, 5, 13]. 
Figure 1 outlines some possible pathophysiological mechanisms of CUA. The main cellular protago-
nists are vascular smooth muscle cells (VSMCs) of the arteriolar media and endothelial cells of the arteri-
olar intima. Macrophages are the main cellular expression of a prominent inflammatory response ob-
served in CUA [13]. All these cells are part of a very specific environment along serum and ECM. 
 
Serum and ECM set the ground for CUA 
 
Serum is the vehicle of major systemic factors strongly associated with CUA, making ECM and cellu-
lar events happen, as described below. It reflects unique characteristics and comorbidities of the CUA 
patient (described in “Clinical aspects”). 
The balance between pro- and anti-calcification factors in the serum is particularly critical in vascular 
ossification-calcification diseases [14], including CUA. Raised serum Ca-P product (CaXP) and the pro-
tein fetuin-A promote and inhibit vascular ossification-calcification, respectively. In general, CaXP is 
increased and fetuin-A is decreased in CUA; however, in a subset of patients, CUA may occur without 
these changes [13, 15]. 
Raised CaXP may be a result of increased serum levels of Ca, P or both. It is a marker of impaired Ca 
and P metabolism in CKD, as well as an independent risk factor of extraskeletal calcification, strongly 
associated with increased mortality [16]. High CaXP was thought to trigger passive precipitation of calci-
um-phosphate crystals in the vessel wall [17]. However, more recent studies refute this simplistic view, 
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showing that, instead of eliciting a passive metastatic calcification process, raised Ca and P levels have an 
active role in changing VSMCs phenotype [15], as detailed later. 
Fetuin-A (α-Heremans Schmid glycoprotein, AHSG) is a circulating inhibitor of vascular ossification-
calcification synthesized in the liver. Due to its high affinity to hydroxyapatite, it tends to accumulate in 
calcification sites. Its transient effects are mediated by “calciprotein particles”, which clear circulating Ca 
and P and therefore selectively inhibit vascular ossification-calcification without interfering in bone min-
eralization [18]. Fetuin-A is also a TGF-β antagonist, acting at a cellular level and interacting with in-
flammatory mediators involved in osteogenesis. As a negative acute-phase reactant, fetuin-A was shown 
to be downregulated in inflammatory states, CKD and CUA patients, which is favourable to vascular 
ossification-calcification [13, 19, 20]. 
Besides serum, ECM also makes a contribution towards a pro-calcifying milieu. ECM remodelling is 
now seen as an early event of CUA: according to recent autopsy studies of skin lesions of CUA, there is a 
marked upregulation of several ECM proteins indicating extensive matrix remodelling in the subcutis 
[21]. These proteins, such as osteopontin, collagen I, fibronectin and laminin, create a pro-calcifying 
ECM environment as they are involved in biomineralization [5]. Another critical ECM protein in CUA is 
the matrix GLA protein (MGP), which may be seen as the ECM equivalent of fetuin-A. 
MGP is a constitutive ECM protein that inhibits vascular ossification-calcification. Like fetuin-A, it is 
particularly present where vascular ossification-calcification happens, and it is synthesised in VSMCs. 
Active MGP forms complexes with fetuin-A and inhibits BMP-2-induced osteogenic differentiation [18, 
22]. γ-Carboxylation is a vitamin K-dependent enzymatic reaction necessary for MGP activity [23]. Thus, 
vitamin K deficiency leads to increased uncarboxylated (inactive) MGP in calcification sites, with a cor-
responding decrease in its circulating fraction. According to ELISA-based studies, inactive MGP is sys-
tematically depleted in the serum of CUA patients [24]. 
   
VSMCs actually make calcification happen 
 
Arteriolar biomineralization basically consists of crystal nucleation and propagation with hydroxyap-
atite deposition in the arteriolar media [3, 5] and is actively performed by VSMCs. VSMCs are pluripo-
tent [9] and may undergo transdifferentiation from a contractile to an osteochondrocytic phenotype, ne-
crosis or apoptosis [25]. These different cellular transformations can promote medial calcification in dif-
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ferent ways. Recently, numerous molecules and signalling pathways have been studied in the VSMCs of 
CUA and CKD patients [15, 26, 27]; their extensive analysis goes beyond this review. 
VSMCs shift into an osteochondrocytic phenotype makes them capable of active osteogenesis. This 
transformation is mainly attributed to inorganic phosphate and presumably does not happen in its absence 
[28]. In addition, uremic toxins, reactive oxygen species, proinflammatory cytokines, hypercalcemia, 
BMP-2 upregulation in endothelial cells and decreased levels of constitutive calcification inhibiting pro-
teins are thought to play a concurrent role by themselves or through facilitation of phosphate action [9, 
13]. Phosphate enters VSMCs via Pit-1 (NaPOC), a sodium-dependent phosphate cotransporter. Through 
this protein, elevated serum phosphate levels translate into increased cytosolic phosphate, which in turn 
upregulates the transcription factor Runx2 (Cbfa-1), promoting differentiation of VSMCs into a secretory 
phenotype. A prominent feature of these cells is the ability to release mineralization-competent matrix 
vesicles [29]. 
Thus, the secretory phenotype corresponds to a proper adaptation of VSMCs to a high phosphate envi-
ronment. VSMCs that maintain their contractile phenotype are said not to be adapted. 
Besides phosphate, systemic hypercalcemia and a pro-calcifying local and systemic milieu seem to 
explain further changes in both adapted and non-adapted VSMCs [30]. 
As a result of these stimuli, secretory (adapted) VSMCs undergo osteochondrocytic differentiation, 
with increased osteopontin and decreased α-actin expression [9, 31]. Consequently, production and re-
lease of matrix vesicles is increased and nanocrystals are endocyted and released into the pro-calcific 
ECM. Release of matrix vesicles is a protective mechanism by preventing intracellular calcium overload, 
but induces ECM calcification [3]. Finally, uptake of nanocrystals by VSMCs induces their senescence 
and apoptosis and triggers new cycles of osteogenic differentiation via BMP-2 and osteopontin upregula-
tion [30, 32]. 
On the contrary, contractile (non-adapted) VSMCs cannot defend themselves from calcium overload, 
which, in the context of high phosphate, triggers their necrosis. Apoptotic and necrotic VSMCs are 
thought to be a nidus for calcification, enhancing the whole process [25]. 
It should be reemphasized that vascular ossification-calcification, albeit necessary, is not enough to 
cause tissue necrosis [12]. Along with medial calcification, VSMCs may promote arteriolar stenosis and 
occlusion through mechanisms interconnected with endothelial cells: intimal hyperplasia and sloughing of 
vascular cells. 
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Intimal hyperplasia is the universal healing response of the vessel wall to insults. Endothelial cells 
dysfunction and injury trigger an inflammatory reaction with release of mediators inducing VSMCs mi-
gration to the intima, proliferation and synthesis of ECM. The consequence of this process is the for-
mation of a permanently thickened neointima, causing arteriolar stenosis [13]. 
Sloughing of vascular cells (VSMCs and endothelial cells) into the vessel lumen may be favoured by 
increased osteopontin expression by VSMCs [31] and results in non-thrombotic arteriolar occlusion. 
 
Endothelial cells add up to the problem 
 
The effect of oscillatory shear stress, inflammatory cytokines and reactive oxygen species (ROS) 
cause BMP-2 upregulation in endothelial cells inducing VSMCs’ osteochondrogenic transdifferentiation 
[5]. 
Endothelial cells contribute to arteriolar stenosis and occlusion through dysfunction, injury, necrosis 
and hyperplasia. 
Endothelial dysfunction consists of complex changes in endothelial cells biology and occurs in a 
broader context of chronic cardiometabolic comorbidities and inflammation. The synthesis of the vasodi-
lator nitric oxide is decreased, which causes vasoconstriction; there is also a preferential synthesis of pro-
coagulant molecules [15]. Increased ROS formation potentiates nitric oxide depletion and leads to injury 
of endothelial cells [9]. 
Injury of endothelial cells arises from endothelial dysfunction and vascular ossification-calcification. 
Injured endothelial cells eventually suffer necrosis and slough into the vascular lumen, promoting subin-
timal fibrosis, non-thrombotic occlusion and thrombogenesis. Histologic studies found destruction of the 
endothelial layer, detached endoluminal CD31+ endothelial cells and signs of total occlusion in subcuta-
neous arterioles of CUA patients [5]. 
Hyperplasia of endothelial cells (not to be confounded with intimal hyperplasia) is an associated histo-
logical finding of CUA [13] which might cause further arteriolar stenosis. BMP-4 may be one of the cul-
prits of this proliferative activity of endothelial cells [5]. 
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Surrounding tissues may also calcify: the Selye’s CUA 
 
Simultaneously to medial arteriolar calcification, there may be calcified deposits in the extravascular 
structures, which in general is associated with more severe CUA [8]. 
One of the possible explanations for the presence of ectopic calcium deposits involves the adipocytes. 
Altered adipocyte biology is one of the hallmarks of chronic inflammation with increased production of 
adipocytokines, boosting local and systemic inflammation [13]. 
Inflammation and associated necrosis of subcutaneous adipose tissue (panniculitis) are thought to dis-
seminate calcium deposition [5], producing deposits in adipose lobules, interadipocyte spaces and subcu-
taneous septa. 
Rare cases of CUA have been described where the most prominent pathologic features are soft tissue 
calcification and necrosis. These patients belong to an extreme of the spectrum of CUA termed “tissue 
calciphylaxis” or “calcifying panniculitis”. Another interesting fact about these cases is the well-defined 
cause-effect relationship between specific precipitating factors, such as injection of iron-dextran or calci-
um heparinate, and CUA [33, 34]. This way of inducing the disease is strikingly similar to the concept of 
calciphylaxis first introduced by Hans Selye, who performed experiments in animals exposed to a set of 
sensitization and challenging factors [11, 35, 36]. 
Despite the differences between experimental and human CUA, Selye’s focus on sensitizing and chal-
lenging factors may be useful to understand some links between the disease and the complexity of the 
CUA patient. 
 
 
Clinical aspects 
 
Risk factors: seeing the patient as a whole 
 
According to the original definition of CUA as a condition of anaphylactic hypersensitivity, this dis-
ease would result from the exposure of a previously sensitized (“allergic”) patient to external challengers 
(“allergens”) [35, 37]. Even though human CUA is not currently regarded as an allergic disease, this 
8 
model remains useful in clinical practice: in the CUA patient, a timely recognition and removal of both 
sensitizing and challenging etiologic agents is key to treatment [12, 38]. 
It is unclear whether some factors involved in this disease are actually causative or only associated. 
This distinction is relevant because associated factors help to identify patients at risk of developing CUA, 
but only true causative factors guide treatment [21, 39]. For instance, hypoalbuminemia is a marker for 
malnutrition and mortality in CKD patients with a strong association with CUA, because it is linked to 
chronic inflammation, dermal loss in ulcerated lesions and reduced fetuin-A levels. However, this factor 
probably does not participate in the pathogenesis of CUA [9, 20]. Randomized controlled trials would 
provide the most accurate confirmation of causality; however, the design of such studies would be a chal-
lenge, considering the rarity of CUA. Due to this limitation, several case-control studies have been per-
formed to identify statistically significant risk factors for the development of CUA. Some of the variables 
consistently associated with CUA include white race, obesity, warfarin and calcitriol therapy and elevated 
serum calcium levels; CUA registries may be helpful in the verification of these associations [40-43]. 
Also, some therapies are risk factors: iatrogeny is thought to play a prominent role in the development of 
CUA [20]. 
Sensitizers confer predisposition to CUA by creating a systemic pro-calcification and pro-
inflammatory milieu. These agents define the patient’s clinical profile: CUA is found in both uremic and 
non-uremic patients, who differ in their clinical backgrounds and sensitizers. 
Uremic CUA occurs in patients with advanced CKD, mainly stage V on chronic dialysis or after renal 
transplantation, and represents the majority of the cases [6, 12, 13]. Hyperphosphatemia, hypercalcemia, 
increased CaXP and secondary hyperparathyroidism are thought to play a central role in the development 
of CUA [38, 44]. High calcium and phosphate diet, treatment with calcium-containing phosphate binders 
and active vitamin D analogs may exacerbate this type of systemic sensitization [13, 44, 45]. Therefore, a 
tight metabolic control is an important effort for successful treatment [13]. 
Non-uremic CUA has been increasingly recognized and affects patients with preserved renal function 
[4, 9, 13]. It is more commonly described in primary hyperparathyroidism. This non-uremic CUA has 
also been reported in patients with autoimmune diseases, chronic inflammatory states, such as Crohn 
disease, connective tissue diseases, sarcoidosis, alcoholic liver disease, and malignant neoplasms [6, 46, 
47]. In patients with autoimmune diseases, CUA is often incorrectly diagnosed as a vasculitic process 
[47]. It should be noted that autoimmune conditions may also contribute to the development of CUA in 
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uremic patients [48]. Thus, anti-inflammatory and antioxidant approaches should be part of the treatment 
of both uremic and non-uremic CUA [13]. 
Uremic and non-uremic CUA patients may share other sensitizers not directly related with inflamma-
tory diseases. Obesity, type II diabetes mellitus, female gender and hypercoagulability may elicit CUA by 
distinct mechanisms. Obesity may compromise arteriolar blood flow to skin and subcutaneous tissues and 
potentiates arteriolar thrombosis. Type II diabetes mellitus is associated with kidney disease, inflamma-
tion and platelet aggregation, which contribute to renal function impairment, endothelial dysfunction and 
arteriolar thrombosis, respectively [9, 38]. Females have a predominantly proximal adipose tissue distri-
bution, where CUA is more common, and hormonal influences (estrogen and leptin) may play a role [39]. 
Hypercoagulability is a systemic influence towards arteriolar thrombosis arising from protein C or S defi-
ciency, obesity or antiphospholipid syndrome [6]. Low molecular weight heparin and tissue plasminogen 
activator have been shown to successfully heal skin lesions in CUA patients supporting the role of hyper-
coagulability [49]. 
In a sensitized uremic or non-uremic patient, challengers act as external acute triggers which precipi-
tate or aggravate clinical manifestations of CUA [20]. Subcutaneous injections, corticosteroids, warfarin, 
antineoplastic drugs, iron salts, erythropoietin and albumin are some potential iatrogenic causes [6, 9, 35, 
46, 50]. All these etiologies are plausible in practice because, in most cases, CUA patients are thoroughly 
followed by nephrologists or internists and, therefore, potentially exposed to overtreatment [20, 39]. 
Warfarin, a vitamin K antagonist commonly used in dialysis patients, inhibits γ-carboxylation reac-
tions, required for the activity of MGP, an anti-calcifying protein located in the ECM. Consequently, 
warfarin increases vascular ossification-calcification processes, which may explain the strong association 
between warfarin use and the development of CUA [20, 40, 41, 44]. 
This division of risk factors into sensitizers and challengers underscores the importance of preventive 
strategies in the management of CUA, but fails to explain why very few uremic patients actually develop 
the disease even if exposed to challenging factors [12, 39]. 
It is clinically relevant to identify the very distinct uremic and non-uremic individuals who may poten-
tially develop CUA. Moreover, diagnosis is even more difficult in non-uremic patients, requiring a high 
index of clinical suspicion [51]. However, non-uremic patients ultimately develop the identical clinical 
presentation and histopathologic findings of classic CUA [13]. 
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Painting the clinical picture and ruling out differential diagnoses 
 
Due to the clinical heterogeneity of CUA in both uremic and non-uremic patients, subgroups of the 
disease with distinct prognoses have been proposed [20, 39]. Skin involvement is more frequent; rare 
cases of CUA affecting internal organs have also been described [52]. 
Visceral CUA has been identified in post-mortem examinations of critically ill patients. Reported clin-
ical presentations include acute respiratory failure [52, 53], gastrointestinal bleeding [54] and widespread 
visceral involvement in a patient with primary autoimmune myelofibrosis [51]. A recent investigation has 
questioned the actual existence of non-cutaneous CUA, pointing the lack of definitive histopathologic 
evidence in some of these autopsy cases [55]. Furthermore, some systemic manifestations associated with 
cutaneous CUA may result from extracutaneous calcification processes not necessarily related to visceral 
CUA [36]. Taking these ideas into consideration, visceral CUA will not be further discussed in this re-
view. 
Cutaneous CUA typically presents as a biphasic process [44, 56]. Each phase may be understood as a 
set of clinical consequences of specific histologic lesions belonging to a continuum towards tissue necro-
sis. ECM remodelling, medial calcification and arteriolar stenosis could be considered “primary lesions”, 
whereas thrombus formation and luminal obstruction leading to tissue infarction have been postulated as 
“secondary lesions” [13, 39]. Primary and secondary lesions might be associated with the first and second 
clinical phases, respectively. 
Phase one usually starts with areas of skin leather-like induration with superimposed pruritic and ex-
cruciatingly painful erythematous nodules, plaques or livedo reticularis. These lesions are more prone to 
appear at adipose tissue sites and become progressively deeper and more extensive. 
Phase two consists of painful ischemic necrosis which manifests as non-healing ulcerations and black 
deep eschars. Infection, abscess formation and gangrene frequently follow the appearance of these lesions 
[6, 9, 10, 35, 36, 38, 56]. 
Acral, distal and penile lesions have a more favourable clinical course, whereas lesions with proximal 
distribution carry a worse prognosis [20, 35, 36, 39, 50]. 
Clinical conditions with prominent vascular involvement and dermatologic manifestations similar to 
CUA belong to an extensive list of differential diagnoses. Some of these diseases are highly prevalent or 
carry a fatal prognosis and must be promptly excluded, namely peripheral artery disease, autoimmune 
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vasculitis, diabetes mellitus-related lower extremity involvement and cholesterol embolization [6, 9, 35, 
39, 44, 57, 58]. In some situations, these diseases may coexist with CUA and should be treated according-
ly. 
In a patient presenting with skin lesions suggesting CUA, a thorough clinical history should be ob-
tained, with particular emphasis on risk factors, and complementary exams need to be performed in order 
to rule out differential diagnoses and establish a definitive diagnosis of CUA [6]. Biochemistry, histo-
pathology and imagiology are the three main vectors of diagnostic investigation, but negative results 
should not be regarded as a warranty of exclusion of the disease [36]. 
Laboratory findings are unspecific, variable and dependent on underlying pathologies. Hyperphos-
phatemia, increased CaXP, hyperparathyroidism and slight hypercalcemia may be found in uremic pa-
tients; elevated canalicular enzymes and albumin are other possible findings in all CUA patients. Howev-
er, both uremic and non-uremic CUA patients may present without these biochemical changes: usage of 
medications in an attempt to correct these metabolic parameters may be one of the reasons for this clinical 
fact [15, 17, 36, 59]. 
Deep skin and subcutaneous tissue incisional biopsy with calcification-sensitive (von Kossa) staining 
is the gold standard for definitive diagnosis [6, 9, 10, 13, 58]. There is controversy on whether biopsy 
should be routinely performed, because this procedure may induce novel non-healing ulcers, existing 
lesions may become more difficult to heal and easier to superinfect and there may be false negative re-
sults [6, 8, 20, 44, 58, 60]. Our institution adopts a very restrictive approach to the use of skin biopsy, 
whose execution is decided on a case-by-case basis, according to the clinical experience of each nephrol-
ogist. Histopathologic findings in CUA, albeit specific, are not pathognomonic and may include one or 
more of the following: medial arteriolar calcification without associated intimal calcification or vasculitic 
changes, intimal hyperplasia, ECM remodelling, soft tissue calcification, thrombosis, epidermal ulcera-
tion and dermal or subcutaneous necrosis [6, 13, 20, 36].  
Imaging modalities may be useful to support histologic results, avoid biopsy or monitor response to 
treatment [61]. Plain soft tissue radiographs may show a typical net-like pattern of vascular calcification 
and irregularity of the soft tissues [8, 61]. Mammography technique is thought to be superior to plain-soft 
tissue x-ray, because it is safe, inexpensive and able to delineate high-contrast microcalcifications which 
cannot be identified in other radiography exams; the main disadvantage of this exam is that it requires the 
compression of the lesions between two plates, causing intense pain [6, 58]. Xeroradiography is described 
12 
by some authors as the optimal way of studying arteriolar and soft tissue calcifications [17, 36, 44]. Bone 
scintigraphy with Tc99m methylene diphosphate detects increased soft tissue uptake of bone tracer in 
areas with noticeable clinical expression, but lacks sensitivity and specificity [8, 39, 44, 57, 60]. 
Once the clinical picture is fully identified and a definitive diagnosis is obtained, patients should 
promptly receive specialized care. However, therapy should ideally begin early in the stage of the disease 
and, many times, before definitive diagnosis. 
 
 
Therapy: to be started in the early stages of CUA 
 
Treatment of CUA remains a series of experimental interventions lacking clinical evidence, with un-
rewarding results and controversial impacts on morbidity and mortality [11, 20, 39]. The various patho-
genic mechanisms involved in CUA support a multimodal approach targeted at distinct aspects of the 
disease, although uremic and non-uremic patients are treated similarly. 
Active treatment of established CUA tends not to be enough. Despite the impressive clinical picture of 
advanced CUA, most of the therapeutic measures are not focused on healing visible lesions but rather on 
treating underlying disease processes and removing iatrogeny [11, 39], which can be done before overt 
CUA develops. In CUA, therapy may be seen as a continuum starting from prevention, which is a very 
important proactive strategy for ‘at risk’ patients [62]. 
 
Withdrawal of iatrogeny and management of underlying disease processes are the mainstay of prevention 
and treatment of CUA 
 
Certain medications that may aggravate systemic sensitization or act as challenging factors in the de-
velopment of CUA should be discontinued, namely vitamin D analogs, subcutaneous injections and war-
farin [44, 57]; the latter may be replaced with “safe” anticoagulants, namely low-molecular weight hepa-
rin, and administration of vitamin K [9, 20, 39]. Corticosteroids belong to a “grey zone” between iatroge-
ny and therapy. On the one hand, prednisolone may be an etiologic agent of CUA and increases infection 
risk of ulcerated lesions; on the other hand, this drug decreases tissue inflammation and has already been 
shown to be effective in some cases [44, 46, 57]. 
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As far as underlying disease processes are concerned, nutritional status and comorbid conditions of 
uremic and non-uremic CUA patients require careful monitoring and treatment [6, 44, 46, 63]. In particu-
lar, control of metabolic parameters is an essential strategy and may be achieved with interventions tar-
geted at phosphate, calcium, CaXP and/or parathormone (PTH) levels, in order to prevent and treat hy-
perphosphatemia, hypercalcemia and/or hyperparathyroidism, respectively. 
Hyperphosphatemia and hypercalcemia require consideration of more intensive dialysis with low cal-
cium dialysate, replacement of oral calcium phosphate binders with non-calcium phosphate binders and 
withdrawal of calcium supplementation [9, 10, 13, 39, 50, 57]. Control of hyperphosphatemia should be 
prioritized over control of hypercalcemia, because phosphate is a requirement for VSMCs to perform 
their active role of arteriolar calcification. In theory, however, induction of transient  hypocalcemia could 
also prove beneficial to normalize CaXP and remove calcium from tissues [44]. 
Hyperparathyroidism may be treated medically or surgically. Cinacalcet is a calcimimetic, suppress-
ing PTH secretion and rapidly correcting calcium and phosphate levels [6, 9, 10, 13, 46]. The EVOLVE 
clinical trial (EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events), 
an event-driven cardiovascular outcomes study, involved the randomization of 3883 hemodialysis pa-
tients with secondary hyperparathyroidism to receive cinacalcet or placebo. 24 patients developed CUA, 
18 in the placebo group and 6 in the cinacalcet group. According to a post-hoc analysis of the results of 
the EVOLVE trial, reduction of serum PTH levels with cinacalcet therapy reduced CUA incidence by 
70%, with a hazard ratio (cinacalcet versus placebo) of 0.25 [64]. For patients with unsatisfactory re-
sponse to medical treatment and evidence of high bone turnover, parathyroidectomy has been proposed 
[9, 10, 13, 20, 46, 57, 65, 66].  Despite the risks of the procedure and unproven benefits on survival, this 
surgery may improve wound healing and tissue oxygenation, especially in patients with very high PTH 
levels [6, 9, 11, 12, 44]. 
As outlined above, CUA may happen in the context of a normal Ca-P metabolism. Thus, systemic 
therapies with antioxidant, anti-inflammatory and antithrombotic mechanisms of action are also used in 
both uremic and non-uremic patients [13]. 
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Sodium thiosulfate: a step forward in therapy 
 
Sodium thiosulphate (STS) is currently regarded as the first-line treatment of patients without hy-
perparathyroidism [6, 13, 46, 50, 57]. 
The mechanism of action of STS is unknown; dissolution of calcium deposits, chelation of calcium 
ions, antioxidant effects and potent vasodilation are some possible effects [6, 9, 11, 13, 39, 46, 57, 67]. 
In 2004, Cicone et al. reported the first successful treatment of CUA with STS, which took inspiration 
from previously reported cases of tumoral calciosis responsive to STS. Dramatic improvements in algic 
complaints, subcutaneous lesions and technetium 99 scans were observed. Also, STS did not produce any 
effects on Ca-P metabolism, which suggests the use of this drug in tandem with a rigorous metabolic 
control. According to these authors, STS could be particularly beneficial in patients unresponsive to other 
therapeutic measures [68]. 
Potential adverse effects of long-term usage of STS remain a concern, especially bone demineraliza-
tion due to STS-induced metabolic acidosis [20]. Other side effects, namely nausea, vomiting, headache, 
hypotension andelectrocardiographic abnormalities, have also been described [9, 13, 20, 46, 57]. 
 
Other strategies also belong to the unfinished equation of therapy 
 
Bisphosphonates are widely used to treat osteoclast-mediated bone loss and have been shown to be 
capable of treating tumoral calcinosis and preventing experimental CUA. These assumptions motivated 
the first use of pamidronate by Monney et al. in the treatment of a patient with rapidly aggravating CUA 
and CKD. Forty-eight hours after the initiation of treatment with pamidronate, a marked improvement in 
the clinical course, with pain reduction and ulcer healing, has been observed [69]. Subsequent studies also 
demonstrated favourable clinical outcomes, which may be mediated by a decrease in inflammation, inhi-
bition of arteriolar calcification and reduction of serum calcium levels through suppression of osteoclastic 
activity. Bisphosphonates have been shown to be effective and well-tolerated, but their use should be 
cautiously considered due to potentially deleterious effects on bone metabolism and renal function [6, 9, 
12, 13, 20, 39, 46, 57, 63]. 
Hyperbaric oxygen (HBO) therapy consists of breathing 100% oxygen in a pressurized environment, 
increasing the amount of dissolved oxygen in the plasma, counteracting local tissue hypoxia and improv-
15 
ing wound healing. Also, HBO is directly bactericidal and bacteriostatic and stimulates neutrophil bacte-
ricidal activity, angiogenesis and fibroblast proliferation. Middle ear barotrauma, pulmonary and central 
nervous system oxygen toxicity, claustrophobia and high monetary costs are some potential problems of 
HBO therapy. Despite its limitations, HBO therapy has been shown to be beneficial in several case re-
ports and retrospective case reviews, especially in patients with distal CUA without secondary hyperpara-
thyroidism, without surgical conditions or refractory to parathyroidectomy [6, 9, 13, 39, 44, 46, 70]. 
According to a matched case-control study, statins may prevent CUA development in dialysis pa-
tients. Anti-inflammatory, antithrombotic and anticalcification properties of these drugs may underlie this 
association between statin use and CUA. Should this association be corroborated, statins may become an 
important strategy for CUA prevention [41]. 
Besides systemic therapies, advanced CUA lesions also require intensive local wound care and pain 
management. Some therapeutic options include debridement of gangrenous tissue, use of broad-spectrum 
antibiotics for superimposed bacterial infection, sterile dressings and pain schedule with opiates [6, 9-11, 
13, 17, 39, 44, 46, 56, 57, 60]. 
 
 
Conclusion 
 
Prognosis of CUA remains poor. Local and systemic infectious complications are responsible for 
short survival and 5-year mortality rates around 60-70% in CUA patients, even when aggressively treated 
with large-spectrum antibiotherapy [9, 10, 17, 36, 57, 66]. 
In this increasingly recognized disease, there is still much to be elucidated on the pathogenesis. Ac-
cording to our revision of the literature, vascular ossification-calcification phenomena in CUA are basi-
cally similar with common uremic vascular ossification-calcification events; however, these mechanisms 
might not explain vascular ossification-calcification in non-uremic patients, where inflammation probably 
assumes a prominent role. As far as diagnosis is concerned, an early identification of ‘at risk’ uremic and 
non-uremic patients is a crucial step for a more successful treatment. Targeted therapies have been men-
tioned in the literature as a promising innovation in the management of CUA [6, 10]. However, it is likely 
that prevention, multidisciplinary care and avoidance of iatrogeny should remain the foundations in the 
management of CUA [11, 20, 45, 50, 56, 66]. 
16 
In summary, many questions on fundamental aspects of this complex disease are yet to be answered, 
deserving further attention by investigators and clinicians. 
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Fig. 1 Calcific uremic arteriolopathy: a multi-layered pathogenesis. This diagram outlines the main 
events in the arteriole and adjacent tissues. From the top to the bottom, like a transverse section of an 
arteriole: lumen; tunica intima; tunica media; extracellular matrix of the arteriole; adipocytes and extra-
cellular matrix of the surrounding dermis, hypodermis or other soft tissue or visceral structure. Various 
influences between systemic and local factors and events were not depicted for clarity. The black box 
signals the main event and histologic finding of calcific uremic arteriolopathy. Gray boxes mark associat-
ed structural changes which can be found in calcific uremic arteriolopathy. See text for further details. Ca 
calcium, Pi inorganic phosphate, CaXP calcium-phosphate product, VSMCs vascular smooth muscle cells, 
MGP matrix GLA protein, BMP bone morphogenetic protein 
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 Do not include titles or captions within your illustrations. 
Figure Numbering 
 All figures are to be numbered using Arabic numerals. 
 Figures should always be cited in text in consecutive numerical order. 
 Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
 If an appendix appears in your article and it contains one or more figures, 
continue the consecutive numbering of the main text. Do not number the 
appendix figures, 
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary 
Material) should, however, be numbered separately. 
Figure Captions 
 Each figure should have a concise caption describing accurately what the figure 
depicts. Include the captions in the text file of the manuscript, not in the figure 
file. 
 Figure captions begin with the term Fig. in bold type, followed by the figure 
number, also in bold type. 
 No punctuation is to be included after the number, nor is any punctuation to be 
placed at the end of the caption. 
 Identify all elements found in the figure in the figure caption; and use boxes, 
circles, etc., as coordinate points in graphs. 
 Identify previously published material by giving the original source in the form 
of a reference citation at the end of the figure caption. 
Figure Placement and Size 
 When preparing your figures, size figures to fit in the column width. 
 For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm 
wide and not higher than 234 mm. 
 For books and book-sized journals, the figures should be 80 mm or 122 mm 
wide and not higher than 198 mm. 
Permissions 
If you include figures that have already been published elsewhere, you must obtain 
permission from the copyright owner(s) for both the print and online format. Please be 
aware that some publishers do not grant electronic rights for free and that Springer will 
not be able to refund any costs that may have occurred to receive these permissions. In 
such cases, material from other sources should be used. 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your 
figures, please make sure that 
 All figures have descriptive captions (blind users could then use a text-to-speech 
software or a text-to-Braille hardware) 
 Patterns are used instead of or in addition to colors for conveying information 
(colorblind users would then be able to distinguish the visual elements) 
 Any figure lettering has a contrast ratio of at least 4.5:1 
Electronic Supplementary Material 
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other 
supplementary files to be published online along with an article or a book chapter. This 
feature can add dimension to the author's article, as certain information cannot be 
printed or is more convenient in electronic form. 
Submission 
 Supply all supplementary material in standard file formats. 
 Please include in each file the following information: article title, journal name, 
author names; affiliation and e-mail address of the corresponding author. 
 To accommodate user downloads, please keep in mind that larger-sized files 
may require very long download times and that some users may experience 
other problems during downloading. 
Audio, Video, and Animations 
 Always use MPEG-1 (.mpg) format. 
Text and Presentations 
 Submit your material in PDF format; .doc or .ppt files are not suitable for long-
term viability. 
 A collection of figures may also be combined in a PDF file. 
Spreadsheets 
 Spreadsheets should be converted to PDF if no interaction with the data is 
intended. 
 If the readers should be encouraged to make their own calculations, spreadsheets 
should be submitted as .xls files (MS Excel). 
Specialized Formats 
 Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica 
notebook), and .tex can also be supplied. 
Collecting Multiple Files 
 It is possible to collect multiple files in a .zip or .gz file. 
Numbering 
 If supplying any supplementary material, the text must make specific mention of 
the material as a citation, similar to that of figures and tables. 
 Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the 
animation (Online Resource 3)", “... additional data are given in Online 
Resource 4”. 
 Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. 
Captions 
 For each supplementary material, please supply a concise caption describing the 
content of the file.  
Processing of supplementary files 
 Electronic supplementary material will be published as received from the author 
without any conversion, editing, or reformatting.  
Accessibility 
In order to give people of all abilities and disabilities access to the content of your 
supplementary files, please make sure that  
 The manuscript contains a descriptive caption for each supplementary material 
 Video files do not contain anything that flashes more than three times per second 
(so that users prone to seizures caused by such effects are not put at risk) 
Ethical Responsibilities of Authors 
This journal is committed to upholding the integrity of the scientific record. As a 
member of the Committee on Publication Ethics (COPE) the journal will follow the 
COPE guidelines on how to deal with potential acts of misconduct.  
Authors should refrain from misrepresenting research results which could damage the 
trust in the journal, the professionalism of scientific authorship, and ultimately the entire 
scientific endeavour. Maintaining integrity of the research and its presentation can be 
achieved by following the rules of good scientific practice, which include: 
 The manuscript has not been submitted to more than one journal for 
simultaneous consideration.  
 The manuscript has not been published previously (partly or in full), unless the 
new work concerns an expansion of previous work (please provide transparency 
on the re-use of material to avoid the hint of text-recycling (“self-plagiarism”)). 
 A single study is not split up into several parts to increase the quantity of 
submissions and submitted to various journals or to one journal over time (e.g. 
“salami-publishing”). 
 No data have been fabricated or manipulated (including images) to support your 
conclusions 
 No data, text, or theories by others are presented as if they were the author’s 
own (“plagiarism”). Proper acknowledgements to other works must be given 
(this includes material that is closely copied (near verbatim), summarized and/or 
paraphrased), quotation marks are used for verbatim copying of material, and 
permissions are secured for material that is copyrighted.  
Important note: the journal may use software to screen for plagiarism. 
 Consent to submit has been received explicitly from all co-authors, as well as 
from the responsible authorities - tacitly or explicitly - at the 
institute/organization where the work has been carried out, before the work is 
submitted. 
 Authors whose names appear on the submission have contributed sufficiently to 
the scientific work and therefore share collective responsibility and 
accountability for the results. 
In addition: 
 Changes of authorship or in the order of authors are not accepted after 
acceptance of a manuscript. 
 Requesting to add or delete authors at revision stage, proof stage, or after 
publication is a serious matter and may be considered when justifiably 
warranted. Justification for changes in authorship must be compelling and may 
be considered only after receipt of written approval from all authors and a 
convincing, detailed explanation about the role/deletion of the new/deleted 
author. In case of changes at revision stage, a letter must accompany the revised 
manuscript. In case of changes after acceptance or publication, the request and 
documentation must be sent via the Publisher to the Editor-in-Chief. In all cases, 
further documentation may be required to support your request. The decision on 
accepting the change rests with the Editor-in-Chief of the journal and may be 
turned down. Therefore authors are strongly advised to ensure the correct author 
group, corresponding author, and order of authors at submission. 
 Upon request authors should be prepared to send relevant documentation or data 
in order to verify the validity of the results. This could be in the form of raw 
data, samples, records, etc. 
If there is a suspicion of misconduct, the journal will carry out an investigation 
following the COPE guidelines. If, after investigation, the allegation seems to raise 
valid concerns, the accused author will be contacted and given an opportunity to address 
the issue. If misconduct has been established beyond reasonable doubt, this may result 
in the Editor-in-Chief’s implementation of the following measures, including, but not 
limited to:  
 If the article is still under consideration, it may be rejected and returned to the 
author.  
 If the article has already been published online, depending on the nature and 
severity of the infraction, either an erratum will be placed with the article or in 
severe cases complete retraction of the article will occur. The reason must be 
given in the published erratum or retraction note.  
 The author’s institution may be informed. 
Compliance with Ethical Standards 
To ensure objectivity and transparency in research and to ensure that accepted principles 
of ethical and professional conduct have been followed, authors should include 
information regarding sources of funding, potential conflicts of interest (financial or 
non-financial), informed consent if the research involved human participants, and a 
statement on welfare of animals if the research involved animals. 
Authors should include the following statements (if applicable) in a separate section 
entitled “Compliance with Ethical Standards” before the References when submitting a 
paper: 
 Disclosure of potential conflicts of interest  
 Research involving Human Participants and/or Animals 
 Informed consent  
Please note that standards could vary slightly per journal dependent on their peer review 
policies (i.e. double blind peer review) as well as per journal subject discipline. Before 
submitting your article check the Instructions for Authors carefully. 
The corresponding author should be prepared to collect documentation of compliance 
with ethical standards and send if requested during peer review or after publication. 
The Editors reserve the right to reject manuscripts that do not comply with the above-
mentioned guidelines. The author will be held responsible for false statements or failure 
to fulfill the above-mentioned guidelines. 
Disclosure of potential conflicts of interest 
Authors must disclose all relationships or interests that could influence or bias the work. 
Although an author may not feel there are conflicts, disclosure of relationships and 
interests affords a more transparent process, leading to an accurate and objective 
assessment of the work. Awareness of real or perceived conflicts of interests is a 
perspective to which the readers are entitled and is not meant to imply that a financial 
relationship with an organization that sponsored the research or compensation for 
consultancy work is inappropriate. Examples of potential conflicts of interests that are 
directly or indirectly related to the research may include but are not limited to the 
following: 
 Research grants from funding agencies (please give the research funder and the 
grant number) 
 Honoraria for speaking at symposia 
 Financial support for attending symposia 
 Financial support for educational programs 
 Employment or consultation 
 Support from a project sponsor  
 Position on advisory board or board of directors or other type of management 
relationships 
 Multiple affiliations 
 Financial relationships, for example equity ownership or investment interest 
 Intellectual property rights (e.g. patents, copyrights and royalties from such 
rights) 
 Holdings of spouse and/or children that may have financial interest in the work 
In addition, interests that go beyond financial interests and compensation (non-financial 
interests) that may be important to readers should be disclosed. These may include but 
are not limited to personal relationships or competing interests directly or indirectly tied 
to this research, or professional interests or personal beliefs that may influence your 
research. 
The corresponding author collects the conflict of interest disclosure forms from all 
authors. In author collaborations where formal agreements for representation allow it, it 
is sufficient for the corresponding author to sign the disclosure form on behalf of all 
authors. Examples of forms can be found 
 here: 
The corresponding author will include a summary statement on the title page that is 
separate from their manuscript, that reflects what is recorded in the potential conflict 
of interest disclosure form(s).  
See below examples of disclosures: 
Funding: This study was funded by X (grant number X). 
Conflict of Interest: Author A has received research grants from Company A. Author 
B has received a speaker honorarium from Company X and owns stock in Company Y. 
Author C is a member of committee Z.  
If no conflict exists, the authors should state:  
Conflict of Interest: The authors declare that they have no conflict of interest. 
Research involving human participants and/or animals 
1) Statement of human rights 
When reporting studies that involve human participants, authors should include a 
statement that the studies have been approved by the appropriate institutional and/or 
national research ethics committee and have been performed in accordance with the 
ethical standards as laid down in the 1964 Declaration of Helsinki and its later 
amendments or comparable ethical standards. 
If doubt exists whether the research was conducted in accordance with the 1964 
Helsinki Declaration or comparable standards, the authors must explain the reasons for 
their approach, and demonstrate that the independent ethics committee or institutional 
review board explicitly approved the doubtful aspects of the study.  
The following statements should be included in the text before the References section: 
Ethical approval: “All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards.” 
For retrospective studies, please add the following sentence: 
“For this type of study formal consent is not required.” 
2) Statement on the welfare of animals 
The welfare of animals used for research must be respected. When reporting 
experiments on animals, authors should indicate whether the international, national, 
and/or institutional guidelines for the care and use of animals have been followed, and 
that the studies have been approved by a research ethics committee at the institution or 
practice at which the studies were conducted (where such a committee exists).  
For studies with animals, the following statement should be included in the text before 
the References section: 
Ethical approval: “All applicable international, national, and/or institutional guidelines 
for the care and use of animals were followed.” 
If applicable (where such a committee exists): “All procedures performed in studies 
involving animals were in accordance with the ethical standards of the institution or 
practice at which the studies were conducted.” 
If articles do not contain studies with human participants or animals by any of the 
authors, please select one of the following statements: 
“This article does not contain any studies with human participants performed by any of 
the authors.” 
“This article does not contain any studies with animals performed by any of the 
authors.” 
“This article does not contain any studies with human participants or animals performed 
by any of the authors.” 
Informed consent 
All individuals have individual rights that are not to be infringed. Individual participants 
in studies have, for example, the right to decide what happens to the (identifiable) 
personal data gathered, to what they have said during a study or an interview, as well as 
to any photograph that was taken. Hence it is important that all participants gave their 
informed consent in writing prior to inclusion in the study. Identifying details (names, 
dates of birth, identity numbers and other information) of the participants that were 
studied should not be published in written descriptions, photographs, and genetic 
profiles unless the information is essential for scientific purposes and the participant (or 
parent or guardian if the participant is incapable) gave written informed consent for 
publication. Complete anonymity is difficult to achieve in some cases, and informed 
consent should be obtained if there is any doubt. For example, masking the eye region 
in photographs of participants is inadequate protection of anonymity. If identifying 
characteristics are altered to protect anonymity, such as in genetic profiles, authors 
should provide assurance that alterations do not distort scientific meaning. 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants 
included in the study.”  
If identifying information about participants is available in the article, the following 
statement should be included: 
“Additional informed consent was obtained from all individual participants for whom 
identifying information is included in this article.” 
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Publisher exclusive publication and dissemination rights). This will ensure the widest 
possible protection and dissemination of information under copyright laws.  
Open Choice articles do not require transfer of copyright as the copyright remains with 
the author. In opting for open access, the author(s) agree to publish the article under the 
Creative Commons Attribution License.. 
Offprints 
Offprints can be ordered by the corresponding author. 
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